vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Urban Edge Properties (UE). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $132.6M, roughly 1.4× Urban Edge Properties). Urban Edge Properties runs the higher net margin — 17.1% vs 13.3%, a 3.7% gap on every dollar of revenue. On growth, Urban Edge Properties posted the faster year-over-year revenue change (12.2% vs -1.8%). Over the past eight quarters, Urban Edge Properties's revenue compounded faster (11.6% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Urban Edge Properties is a publicly traded real estate investment trust (REIT) that owns, operates, and develops high-quality retail and mixed-use properties, primarily located in densely populated urban and suburban markets across the United States. Its portfolio covers grocery-anchored shopping centers, lifestyle outlets, and community-focused commercial assets.
AMPH vs UE — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $132.6M |
| Net Profit | $24.4M | $22.6M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 17.1% |
| Revenue YoY | -1.8% | 12.2% |
| Net Profit YoY | -35.7% | -6.7% |
| EPS (diluted) | $0.51 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $132.6M | ||
| Q4 25 | $183.1M | $119.6M | ||
| Q3 25 | $191.8M | $120.1M | ||
| Q2 25 | $174.4M | $114.1M | ||
| Q1 25 | $170.5M | $118.2M | ||
| Q4 24 | $186.5M | $116.4M | ||
| Q3 24 | $191.2M | $112.4M | ||
| Q2 24 | $182.4M | $106.5M |
| Q1 26 | — | $22.6M | ||
| Q4 25 | $24.4M | $12.4M | ||
| Q3 25 | $17.4M | $14.9M | ||
| Q2 25 | $31.0M | $58.0M | ||
| Q1 25 | $25.3M | $8.2M | ||
| Q4 24 | $38.0M | $30.1M | ||
| Q3 24 | $40.4M | $9.1M | ||
| Q2 24 | $37.9M | $30.8M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 11.3% | ||
| Q3 25 | 13.2% | 13.4% | ||
| Q2 25 | 24.2% | 53.9% | ||
| Q1 25 | 21.9% | 7.6% | ||
| Q4 24 | 24.2% | 27.6% | ||
| Q3 24 | 29.8% | 8.9% | ||
| Q2 24 | 30.3% | 30.6% |
| Q1 26 | — | 17.1% | ||
| Q4 25 | 13.3% | 10.4% | ||
| Q3 25 | 9.0% | 12.4% | ||
| Q2 25 | 17.8% | 50.8% | ||
| Q1 25 | 14.8% | 6.9% | ||
| Q4 24 | 20.4% | 25.9% | ||
| Q3 24 | 21.1% | 8.1% | ||
| Q2 24 | 20.8% | 28.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $0.51 | $0.09 | ||
| Q3 25 | $0.37 | $0.12 | ||
| Q2 25 | $0.64 | $0.46 | ||
| Q1 25 | $0.51 | $0.07 | ||
| Q4 24 | $0.74 | $0.25 | ||
| Q3 24 | $0.78 | $0.07 | ||
| Q2 24 | $0.73 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $50.0M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.4B |
| Total Assets | $1.6B | $3.4B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $50.0M | ||
| Q4 25 | $282.8M | $48.9M | ||
| Q3 25 | $276.2M | $77.8M | ||
| Q2 25 | $231.8M | $53.0M | ||
| Q1 25 | $236.9M | $48.0M | ||
| Q4 24 | $221.6M | $41.4M | ||
| Q3 24 | $250.5M | $67.9M | ||
| Q2 24 | $217.8M | $78.6M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $788.8M | $1.4B | ||
| Q3 25 | $776.7M | $1.4B | ||
| Q2 25 | $757.5M | $1.4B | ||
| Q1 25 | $751.3M | $1.4B | ||
| Q4 24 | $732.3M | $1.4B | ||
| Q3 24 | $727.7M | $1.3B | ||
| Q2 24 | $713.3M | $1.3B |
| Q1 26 | — | $3.4B | ||
| Q4 25 | $1.6B | $3.3B | ||
| Q3 25 | $1.7B | $3.3B | ||
| Q2 25 | $1.6B | $3.3B | ||
| Q1 25 | $1.6B | $3.3B | ||
| Q4 24 | $1.6B | $3.3B | ||
| Q3 24 | $1.5B | $3.2B | ||
| Q2 24 | $1.5B | $3.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $39.1M |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.73× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $39.1M | ||
| Q4 25 | $32.9M | $182.7M | ||
| Q3 25 | $52.6M | $55.7M | ||
| Q2 25 | $35.6M | $43.5M | ||
| Q1 25 | $35.1M | $32.6M | ||
| Q4 24 | $29.0M | $153.2M | ||
| Q3 24 | $60.0M | $36.6M | ||
| Q2 24 | $69.1M | $41.2M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $81.8M | ||
| Q3 25 | $47.2M | $26.1M | ||
| Q2 25 | $25.0M | $19.6M | ||
| Q1 25 | $24.4M | $11.9M | ||
| Q4 24 | $16.6M | $42.5M | ||
| Q3 24 | $46.2M | $12.2M | ||
| Q2 24 | $63.1M | $19.9M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 68.4% | ||
| Q3 25 | 24.6% | 21.7% | ||
| Q2 25 | 14.3% | 17.2% | ||
| Q1 25 | 14.3% | 10.0% | ||
| Q4 24 | 8.9% | 36.6% | ||
| Q3 24 | 24.1% | 10.8% | ||
| Q2 24 | 34.6% | 18.6% |
| Q1 26 | — | 1.5% | ||
| Q4 25 | 4.5% | 84.4% | ||
| Q3 25 | 2.8% | 24.6% | ||
| Q2 25 | 6.1% | 20.9% | ||
| Q1 25 | 6.3% | 17.5% | ||
| Q4 24 | 6.7% | 95.1% | ||
| Q3 24 | 7.2% | 21.7% | ||
| Q2 24 | 3.3% | 20.1% |
| Q1 26 | — | 1.73× | ||
| Q4 25 | 1.35× | 14.71× | ||
| Q3 25 | 3.03× | 3.73× | ||
| Q2 25 | 1.15× | 0.75× | ||
| Q1 25 | 1.39× | 3.97× | ||
| Q4 24 | 0.76× | 5.09× | ||
| Q3 24 | 1.48× | 4.03× | ||
| Q2 24 | 1.82× | 1.34× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
UE
| Rental revenue | $124.2M | 94% |
| Other | $8.4M | 6% |
